These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9092347)

  • 21. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
    J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nicotinic cholinergic receptor and myasthenia gravis].
    Tu LH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1983 Aug; 16(4):250-3. PubMed ID: 6315322
    [No Abstract]   [Full Text] [Related]  

  • 23. Myasthenia gravis: nicotinic acetylcholine receptors as targets for autoimmune attack.
    Newsom-Davis J; Harcourt G; Beeson D
    Biochem Soc Trans; 1989 Aug; 17(4):635-7. PubMed ID: 2670631
    [No Abstract]   [Full Text] [Related]  

  • 24. Three-dimensional location of the main immunogenic region of the acetylcholine receptor.
    Beroukhim R; Unwin N
    Neuron; 1995 Aug; 15(2):323-31. PubMed ID: 7544140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial occurrence of autoimmune myasthenia gravis with different antibody specificity.
    Lavrnic D; Nikolic A; De Baets M; Verschuuren J; Verduyn W; Losen M; Stojanovic V; Stevic Z; Hajdukovic Lj; Apostolski S
    Neurology; 2008 May; 70(21):2011-3. PubMed ID: 18490624
    [No Abstract]   [Full Text] [Related]  

  • 26. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function.
    Vincent A; Li Z; Hart A; Barrett-Jolley R; Yamamoto T; Burges J; Wray D; Byrne N; Molenaar P; Newsom-Davis J
    Ann N Y Acad Sci; 1993 Jun; 681():529-38. PubMed ID: 8395163
    [No Abstract]   [Full Text] [Related]  

  • 27. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
    Psaridi-Linardaki L; Trakas N; Mamalaki A; Tzartos SJ
    J Neuroimmunol; 2005 Feb; 159(1-2):183-91. PubMed ID: 15652418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human muscle acetylcholine receptor reactive T and B lymphocytes in myasthenia gravis.
    Yi Q; Lefvert AK
    Ann N Y Acad Sci; 1993 Jun; 681():339-41. PubMed ID: 8357186
    [No Abstract]   [Full Text] [Related]  

  • 29. Purified IgG from seropositive and seronegative patients with mysasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels.
    Bufler J; Pitz R; Czep M; Wick M; Franke C
    Ann Neurol; 1998 Apr; 43(4):458-64. PubMed ID: 9546326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis.
    Somnier FE
    Neurology; 2005 Sep; 65(6):928-30. PubMed ID: 16186537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferative responses to acetylcholine receptor peptides in myasthenia gravis.
    Berrih-Aknin S; Cohen-Kaminsky S; Neumann D; Bach JF; Fuchs S
    Ann N Y Acad Sci; 1988; 540():504-5. PubMed ID: 2462824
    [No Abstract]   [Full Text] [Related]  

  • 32. Blood and thymic lymphocyte responses to peptide sequences of the acetylcholine receptor in myasthenia gravis.
    Harcourt G; Sommer N; Rothbard J; Beeson D; Willcox N; Newsom-Davis J
    Ann N Y Acad Sci; 1988; 540():354-6. PubMed ID: 2462811
    [No Abstract]   [Full Text] [Related]  

  • 33. A simplified ELISA for anti-receptor antibodies in myasthenia gravis.
    Jailkhani BL; Asthana D; Jaffery NF; Kumar R; Ahuja GK
    J Immunol Methods; 1986 Jan; 86(1):115-8. PubMed ID: 3944465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis.
    Sato T; Ishigaki Y; Komiya T; Tsuda H
    Ann N Y Acad Sci; 1988; 540():554-6. PubMed ID: 3061349
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of immunological fine-specificity on the induction of experimental myasthenia gravis.
    Krolick KA; Thompson PA; Zoda TE; Yeh TM
    Ann N Y Acad Sci; 1993 Jun; 681():179-97. PubMed ID: 7689305
    [No Abstract]   [Full Text] [Related]  

  • 36. Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function.
    Venter JC; Berzofsky JA; Lindstrom J; Jacobs S; Fraser CM; Kohn LD; Schneider WJ; Greene GL; Strosberg AD; Erlanger BF
    Fed Proc; 1984 Jul; 43(10):2532-9. PubMed ID: 6203777
    [No Abstract]   [Full Text] [Related]  

  • 37. Correlating extent of neuromuscular instability with acetylcholine receptor antibodies.
    Farrugia ME; Jacob S; Sarrigiannis PG; Kennett RP
    Muscle Nerve; 2009 Apr; 39(4):489-93. PubMed ID: 19260064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of autoimmune helper T lymphocytes from patients with myasthenia gravis with synthetic peptides of the acetylcholine receptor alpha subunit.
    Hohlfeld R; Toyka KV; Miner LL; Conti-Tronconi BM
    Ann N Y Acad Sci; 1988; 540():511-2. PubMed ID: 2462826
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular mimicry and microorganisms: a role in the pathogenesis of myasthenia gravis?
    Dieperink ME; Stefansson K
    Curr Top Microbiol Immunol; 1989; 145():57-65. PubMed ID: 2478337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.